Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lithium carbonate
Drug ID BADD_D01303
Description Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Indications and Usage Lithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.
Marketing Status Prescription; Discontinued
ATC Code N05AN01
DrugBank ID DB14509
KEGG ID D00801
MeSH ID D016651
PubChem ID 11125
TTD Drug ID D04UUH
NDC Product Code 72789-173; 68462-222; 71610-557; 0220-3128; 0054-2531; 31722-546; 68462-224; 0054-0021; 71335-0120; 64117-256; 50090-1470; 46708-303; 70518-0437; 51079-180; 0054-8527; 0054-8526; 0054-2527; 62559-280; 0054-0020; 50090-2799; 0378-1450; 68084-655; 51079-142; 0378-1300; 68462-221; 0054-4527; 70518-0904; 50090-2959; 46708-304; 68084-640; 71335-1067; 0220-3129; 63629-7730; 66039-947; 58118-0545; 70518-0668; 62332-013; 72789-174; 50090-2754; 73309-248; 63629-1916; 64980-278; 82388-001; 0054-2526; 70518-2312; 63629-8282; 63629-1917; 55154-4920; 68428-481; 62332-014; 62756-430; 0054-8528; 70518-0608; 64980-205; 42291-496; 62332-015; 70518-2345; 68462-220; 50090-3918; 23155-763; 68788-7716; 0220-3131; 63187-304; 70518-1753; 71335-1006; 46708-305; 46708-148; 70518-2086; 62332-148; 31722-544; 63629-7903; 68462-223; 72789-171; 72789-172; 50090-3917; 0615-8302; 70518-2699; 0054-8531; 39345-5104; 43063-901; 70518-1434; 31722-545
Synonyms Lithium Carbonate | Carbonate, Lithium | Dilithium Carbonate | Carbonate, Dilithium | Lithane | Lithium Bicarbonate | Bicarbonate, Lithium | Lithobid | Lithonate | CP-15,467-61 | CP 15,467 61 | CP15,46761 | Micalith | NSC-16895 | NSC 16895 | NSC16895 | Priadel | Quilinorm-retard | Quilinorm retard | Quilinormretard | Eskalith | Lithotabs
Chemical Information
Molecular Formula CLi2O3
CAS Registry Number 554-13-2
SMILES [Li+].[Li+].C(=O)([O-])[O-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Nephrogenic diabetes insipidusVasopressin V2 receptorP48044Not AvailableNot Available
Renal aplasiaVasopressin V2 receptorP48044Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Constipation07.02.02.0010.002453%
Coordination abnormal17.02.02.004--Not Available
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Creatinine renal clearance decreased13.13.01.013--Not Available
Crying17.02.05.013; 12.02.11.001; 08.01.03.005; 19.04.02.0020.000818%Not Available
Death08.04.01.001--
Dehydration14.05.05.0010.006133%
Delirium19.13.02.0010.003271%
Dementia19.20.02.001; 17.03.01.0010.002044%Not Available
Dental caries07.09.01.001--
Depressed level of consciousness17.02.04.0020.001635%
Depressed mood19.15.02.0010.001227%Not Available
Dermatitis23.03.04.002--Not Available
Diabetes insipidus14.05.07.003; 05.03.03.0040.003271%Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disorientation17.02.05.015; 19.13.01.0020.002044%Not Available
Disturbance in attention17.03.03.001; 19.21.02.0020.001227%
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drooling17.02.05.0050.000818%Not Available
Drug abuse19.07.02.010--Not Available
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000818%Not Available
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysarthria19.19.03.001; 17.02.08.0010.005724%
Dysgeusia17.02.07.003; 07.14.03.001--
Dyskinesia17.01.02.0060.000818%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 11 Pages